
Tick populations are expanding across the U.S., driven by warmer temperatures and shifting landscapes.
Lyme disease cases have tripled since the 1990s, yet prevention has remained underfunded for decades.
Now Pfizer is moving toward FDA approval for a Lyme vaccine.
The timing raises questions worth asking, given Big Pharma's history of profiting from conditions shaped by environmental neglect.
Addressing tick habitat through land stewardship may matter as much as any pharmaceutical solution.

English
























